# US 2013/0253195 A1 · Process for preparing bosentan monohydrate and its intermediated

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253195 A1
- Document ID: US20130253195A1
- Status: Published application
- Kind: A1
- Application number: 13/824,620
- Filed: 2011-09-22
- Published: 2013-09-26
- Earliest claimed: 2010-10-01
- Assignees: Zach System S.P.A.
- Inventors: Livius Cotarca; Massimo Verzini; Elisa Melotto; Ivan Michieletto; Alfonso Melloni; Paolo Maragni; Raffaella Volpicelli; Mauro Andretto; Corrado Colli
- Web page: https://patentgrep.com/patent/US20130253195A1

## CPC

- C07D 239/69: Benzenesulfonamido-pyrimidines
- A61P 9/12: Antihypertensives
- C07C 31/202: {Ethylene glycol}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to a process for preparing Bosentan Monohydrate; in particular, the present invention provides the preparation of the novel 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yl]-benzenesulfonamide sodium salt as an ethylene glycol solvate (Bosentan sodium salt ethylene glycol solvate), which is a useful intermediate for obtaining Bosentan Monohydrate in a pure form.

## Claims

### Claim 1

Crystalline form of Bosentan sodium salt of formula (IV)
wherein the crystalline form comprises, as part of its crystalline structure, stoichiometric or non-stoichiometric amount of ethylene glycol.

### Claim 2 (depends on 1)

Crystalline form of ethylene glycol solvate of Bosentan sodium salt according to claim 1, having a XRPD comprising peaks expressed at the following degrees two-theta values: 6.4, 8.4, 9.0, 9.9, 12.0, 18.2 and 20.4, plus or minus 0.2 degrees.

### Claim 3 (depends on 1)

A process for preparing Bosentan sodium salt as ethylene glycol solvate according to claim 1 comprising:
a) coupling 4-tert-butyl-N-[6-chloro-5-(2-methoxy-phenoxy)-2-(2-pyrimidin-yl)-pyrimidin-4-yl]benzenesulfonamide potassium salt of formula (II)
with sodium ethylene glycolate of formula (III)
operating in ethylene glycol as a solvent, heating the reaction mixture at a temperature ranging from 65° C. to 75° C.;
b) allowing or promoting the precipitation of the desired Bosentan sodium salt as ethylene glycol solvate; and
c) recovering it from the reaction mixture.

### Claim 4 (depends on 3)

A process according to claim 3, wherein Bosentan sodium salt ethylene glycol solvate is collected as a wet cake, wherein residual ethylene glycol is about 20% to about 40%.

### Claim 5 (depends on 3)

A process for preparing Bosentan sodium salt as ethylene glycol solvate according to claim 3, wherein the compound of formula (III) is obtained by reacting sodium methoxide (CH3ONa) with ethylene glycol.

### Claim 6 (depends on 1)

Method for preparing Bosentan Monohydrate of formula I with the crystalline form of ethylene glycol solvate of Bosentan sodium salt according to claim 1

### Claim 7

Bosentan sodium salt of formula (IV)
comprising dimer impurity of formula (Ia) and pyrimidinone impurity of formula (Ib)
wherein total content of such impurities is less than 0.3% as measured by high performance liquid chromatography (“HPLC”).

### Claim 8 (depends on 7)

Bosentan sodium salt according to claim 7, wherein the total content of dimer and pyrimidinone impurities is less than about 0.2% as measured by HPLC.

### Claim 9 (depends on 8)

Bosentan sodium salt according to claim 8, wherein the total content of dimer and pyrimidinone impurities is less than about 0.1% as measured by HPLC.

### Claim 10 (depends on 7)

Bosentan sodium salt of formula (IV) according to claim 7, having a XRPD comprising peaks expressed at the following degrees two-theta values 6.6, 7.8, 9.0, 10.2 and 25.2, plus or minus 0.2 degrees.

### Claim 11 (depends on 7)

A process for preparing Bosentan Monohydrate of formula (I)
which comprises:
a) coupling 4-tert-butyl-N-[6-chloro-5-(2-methoxy-phenoxy)-2-(2-pyrimidin-yl)-pyrimidin-4-yl]-benzenesulfonamide potassium salt of formula
with sodium ethylene glycolate of formula (III)
operating in ethylene glycol as a solvent, heating the reaction mixture at a temperature ranging from 65° C. to 75° C. to give Bosentan sodium salt of formula (IV) as a ethylene glycol solvate
b) allowing or promoting the precipitation Bosentan sodium salt as ethylene glycol solvate from the reaction mixture;
c) recovering Bosentan sodium salt as ethylene glycol solvate from the reaction mixture;
d) providing a solution of Bosentan sodium salt ethylene glycol solvate of formula (IV) in ethanol alone or in a mixture with acetone and/or cyclohexane at a temperature ranging from 65° C. to 750;
e) allowing or promoting pure Bosentan sodium salt of formula (IV) to crystallize from the solution;
f) recovering the pure Bosentan sodium salt of formula (IV); and
g) converting the pure Bosentan sodium salt into Bosentan Monohydrate of formula (I);
wherein the dimer impurity of formula (Ia) and the pyrimidinone impurity of formula (Ib) as defined in claim 7 which can be generated when performing reaction steps a) to d), remain in the supernatant solution when Bosentan sodium salt is obtained under reaction steps e) and f).

### Claim 12 (depends on 11)

A process according to claim 11, wherein the solution of Bosentan sodium salt ethylene glycol solvate of step c) is provided by dissolving Bosentan sodium salt ethylene glycol solvate as obtained according to step b) in a mixture of ethanol, acetone and cyclohexane as a solvent, wherein at least 80% per weight of the solvent is ethanol.

### Claim 13 (depends on 11)

A process according to claim 11, wherein the precipitation of the crystalline pure form of Bosentan sodium salt according to step e) is initiated or promoted by seeding the reaction mixture with “seeds” of crystals of pure Bosentan sodium salt, in order to induce crystallization of pure form of Bosentan sodium salt.

### Claim 14 (depends on 13)

A process according to claim 13, wherein the “seeds” of crystals of pure Bosentan sodium salt are charged before adding the solvent.
